Our findings reveal that Cyp51 isozyme selectivity represents a previously underexplored mechanism for antifungal synergy, providing a rational basis for precision combination therapies with enhanced efficacy against dermatophytosis and other fungal infections. This evidence concerns the gene CYP51A1 and fungal infectious disease.